Christophe Pouchoy, Managing Director and General Manager, co-manager of the Trecento Santé fund, answered Pharmaceutical magazine’s questions about the growth and profitability of the pharmaceutical and biotech sector. He also explained the favorable impact for the US tax reform sector.
“For big pharma, which has a significant turnover in the US market, the largest in the world, the tax reform has mechanically increased their net margins, which will allow them to increase the return of capital. shareholders (dividends, share repurchases), to continue their acquisitions or (…) “
Read the article by clicking here (available in French only)